

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

HANSON ET AL

GROUP ART UNIT: 1621

SERIAL NUMBER: 09/996,343

EXAMINER: M.L. SHIPPEN

FILED: 28 NOV 01

DATE: 11 MAR 03

TITLE: USE OF PROPARGYL GLYCINE AMINO PROPARGYL DIOL COMPOUNDS FOR PREVENTION OF HYPERTENSION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner of Patents and Trademarks,
Washington D.C., 20231 on 11 MAR 03
J. Timothy Keane
Registration No. 27,808


Date: 11 March 2003**TERMINAL DISCLAIMER**

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

03/25/2003 MASTIN 00000010 191025 09996343
110.00 CH

I, J. Timothy Keane, represent that I am the attorney of record for this invention, that Pharmacia Corporation, parent company of G.D. Searle & Co., P.O. Box 1027, Chesterfield, MO 63006, a corporation in the State of Delaware, owns all of the right, title and interest in the above-identified application Serial No. 09/996,343, is a divisional of U.S. Application Serial No. 09/479,280, filed 6 January 2000, which issued as U.S. Patent No. 6,342,624, which is a continuation of Application Serial No. 09/969,522 filed on 13 November 1997, which is a continuation of Application Serial No. 08/771,334, filed on 16 January 1996, which is a continuation of Application Serial No. 08/199,237, filed 28 February 1994, which issued 16 January 1996 as U.S. Patent 5,484,812, which is a continuation-in-part of Application Serial No. 07/784,272, filed on 29 October 1991, which issued on 29 June 1993 as U.S. Patent 5,223,535.


Your petitioner, J. Timothy Keane, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 for U.S. Patent No. 5,223,535 and/or U.S. Patent No. 6,342,624, and hereby agrees enforceable only for and during such period that the legal title to such patent shall be the same as the legal title to U.S. Patent No. 5,223,535 and/or U.S. Patent No. 6,342,624, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer petitioner does not disclaim any terminal part of any patent granted on the above-identified application that would extend to the expiration date of the full or extended statutory term as defined in 35 U.S.C. 154 to 156 and 173 in the event that U.S. Patent No. 5,223,535 and/or U.S. Patent No. 6,342,624 later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims canceled by a reexamination certificate, is reissued, or is otherwise terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Further, the petitioner does not disclaim any right to extend the term of any patent issued for the above-identified application under 35 U.S.C. 156 from the date of expiration for such patent as is imposed by this terminal disclaimer.

The evidentiary documents accompanying or referred to in the Instant Terminal Disclaimer have been reviewed by the undersigned and it is certified that to the best of my knowledge and belief, title is in the assignee.

Signature

 J. Timothy Keane
Attorney of Record
Reg. No. 27,808
Tel: 314-274-9090

Dated: 11 March 2003

PHARMACIA CORPORATION
Global Patent Department
P.O. Box 1027
Chesterfield, MO 63006